CerebraAI ASPECTS Module
Automated ASPECTS scoring for ischemic stroke assessment
Approved (KZ) / Pre-market (US)Approved in Kazakhstan (2021). FDA BDD submission in 2024.
Key Facts
Indication
Automated ASPECTS scoring for ischemic stroke assessment
Phase
Approved (KZ) / Pre-market (US)
Status
Approved in Kazakhstan (2021). FDA BDD submission in 2024.
Company
About Cerebra AI
Cerebra AI's mission is to create AI solutions that are essential, not just 'nice to have,' in emergency medicine, aiming to improve outcomes when every second counts. Founded from an AI lab in Kazakhstan, the company has achieved significant milestones including regulatory approval in Kazakhstan, deployment in over 50 hospitals, and a growing proprietary dataset of over 150,000 patients. With a strategic relocation to the U.S. and a pending FDA submission, Cerebra AI is positioning itself to become a key player in the global AI-powered neuroimaging diagnostics market.
View full company profile